ClinicalTrials.gov
public full text
Public Domain
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
The purpose of this study is to find the safest dose and identify any bad side effects of EGFR-BATs (bispecific antibody-armed activated T cells) for people with advanced pancreatic cancer who have already received first-line standard chemotherapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer#245557
- Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer#890217
- Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer#872070
- Vaccine Study for Surgically Resected Pancreatic Cancer#481792
- A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer#879040
Record · ID 994893
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive